Home | GSK US
January 07 2025 GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma
Careers | GSK US
At GSK, we unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.
Products - GSK US
Our portfolio of more than 20 marketed vaccines is one of the industry’s broadest. We deliver over 1.5 million doses of our vaccines every day; and 4 out of 10 infants born each year receive at …
US FDA accepts GSK’s submission for the use of Nucala …
Dec 9, 2024 · GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study to support the regulatory review process to obtain a new indication for the use of Nucala (mepolizumab), as an add-on maintenance treatment for patients with chronic obstructive pulmonary disease (COPD) with …
Search jobs - GSK US
Explore our career opportunities all over the world
Press releases - GSK US
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma Regulatory designation based on promising early data in this rare bone cancer.
Therapeutic areas - GSK US
Explore innovations in medicines and healthcare from inside and outside our labs. Discover more about what we do, the people behind GSK and how we operate responsibly for all our stakeholders by prioritizing Innovation, Performance and Trust.
Contact us - GSK
Contact us online at GSK for You. RRC - a reimbursement support program that helps patients and healthcare professionals in the US with coverage, coding and reimbursement issues for …
Sitemap - GSK US
GSK hosts first “Protecting our communities” LinkedIn Live series GSK hosts second “Protecting our communities” LinkedIn Live event Breaking barriers for better COPD care Choosing the best treatment plan for you Breaking the stigma of COPD If you are 50 and older, there is risk for shingles. Linking a chapter of GSK history for seeking ...
Belantamab Mafodotin shows significant overall survival benefit ...
Dec 9, 2024 · GSK plc (LSE/NYSE: GSK) today announced statistically significant and clinically meaningful overall survival (OS) results from a planned interim analysis of the DREAMM-7 trial …